# Efficacy and Safety of Telmisartan Compared With Losartan

> **NCT06431477** · PHASE4 · RECRUITING · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 98 (estimated)

## Conditions studied

- Diabetic Nephropathies
- Hypertension

## Interventions

- **DRUG:** telmisartan
- **DRUG:** Losartan

## Key facts

- **NCT ID:** NCT06431477
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-19
- **Primary completion:** 2025-10-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2024-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06431477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06431477, "Efficacy and Safety of Telmisartan Compared With Losartan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06431477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*